Alnylam Pharmaceuticals
ALNY
#545
Rank
ยฃ29.25 B
Marketcap
ยฃ227.90
Share price
-1.26%
Change (1 day)
67.22%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): ยฃ60.45 Million

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are ยฃ2.34 Billion. In 2023 the company made an earning of -ยฃ0.24 Billion, an increase over its 2022 earnings that were of -ยฃ0.75 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) ยฃ60.45 M-125.21%
2023 -ยฃ0.24 Billion-67.84%
2022 -ยฃ0.75 Billion36.93%
2021 -ยฃ0.55 Billion-8.04%
2020 -ยฃ0.6 Billion-15.66%
2019 -ยฃ0.71 Billion12.23%
2018 -ยฃ0.63 Billion62.91%
2017 -ยฃ0.39 Billion17.78%
2016 -ยฃ0.33 Billion43.44%
2015 -ยฃ0.23 Billion60.69%
2014 -ยฃ0.15 Billion98.2%
2013 -ยฃ71.38 Million
2011 -ยฃ42.1 Million27.48%
2010 -ยฃ33.03 Million-10.92%
2009 -ยฃ37.08 Million95.77%
2008 -ยฃ18.94 Million
2006 -ยฃ30.34 Million-9.13%
2005 -ยฃ33.39 Million34.74%
2004 -ยฃ24.78 Million36.79%
2003 -ยฃ18.12 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ0.41 Billion-861.40%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.52 B 6,544.07%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ47.78 M-9.88%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.19 Billion-454.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ26.88 Million-150.69%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ8.37 B 15,686.04%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ5.18 B 9,676.31%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ0.63 B 1,097.82%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel